Discontinued — last reported Q4 '19
Other Financing
FinancingEli Lilly Other Financing increased by 16.9% to -$25.10M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 44.8%, from -$45.50M to -$25.10M. Over 4 years (FY 2021 to FY 2025), Other Financing shows a downward trend with a 27.1% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ1 2017
Last reportedQ4 2019
How to read this metric
Large values in this category may indicate complex financing arrangements or significant tax impacts from equity-based employee compensation.
Detailed definition
A residual category in the financing section of the cash flow statement that captures miscellaneous cash inflows and out...
Peer comparison
Most S&P 500 companies use this as a 'catch-all' for small financing adjustments, though the specific components vary by accounting policy.
Metric ID:
cf_other_financingHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$14.90M | -$500.00K | -$600.00K | -$282.40M | -$7.60M | -$5.20M | -$13.70M | -$281.00M | -$15.60M | -$6.80M | -$31.60M | -$389.80M | -$8.00M | -$47.30M | -$45.50M | -$686.30M | -$30.40M | -$30.20M | -$25.10M |
| QoQ Change | — | +96.6% | -20.0% | <-999% | +97.3% | +31.6% | -163.5% | <-999% | +94.4% | +56.4% | -364.7% | <-999% | +97.9% | -491.2% | +3.8% | <-999% | +95.6% | +0.7% | +16.9% |
| YoY Change | — | — | — | — | +49.0% | -940.0% | <-999% | +0.5% | -105.3% | -30.8% | -130.7% | -38.7% | +48.7% | -595.6% | -44.0% | -76.1% | -280.0% | +36.2% | +44.8% |
Range-$686.30M – -$500.00K
CAGR+12.3%
Avg YoY Growth-283.0%
Median YoY Growth-44.0%
Current Streak3 quarters growth
Other Financing at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other financing?
- Eli Lilly (LLY) reported other financing of -$25.10M in Q4 2025.
- How has Eli Lilly's other financing changed year-over-year?
- Eli Lilly's other financing increased by 44.8% year-over-year, from -$45.50M to -$25.10M.
- What is the long-term trend for Eli Lilly's other financing?
- Over 4 years (2021 to 2025), Eli Lilly's other financing has grown at a 27.1% compound annual growth rate (CAGR), from -$295.90M to -$772.00M.
- What does other financing mean?
- Miscellaneous cash transactions related to how the company is funded that don't fit into major categories like debt or dividends.